β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 3, 2005, Pages 127-137

  Terra, Steven G ^b   Pauly, Daniel F ^b   Lee, Craig R ^b   Patterson, J Herbert ^b   Adams Jr , Kirkwood F ^b   Schofield, Richard S ^b   Belgado, Bernadette S ^b   Hamilton, Karen K ^b   Aranda, Juan M ^b   Hill, James A ^b   Yarandi, Hossein N ^b   Walker, Joseph R ^b   Phillips, Michael S ^b   Gelfand, Craig A ^b   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; METOPROLOL; METOPROLOL SUCCINATE; SERINE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CODON; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; DNA POLYMORPHISM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENOTYPE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; EXERCISE TOLERANCE; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA; TIME AND MOTION STUDIES; TREATMENT OUTCOME;

EID: 13944259802     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.10.006     Document Type: Article

References (41)

1. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, G.S. Grancis ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 38 2001 2101 2113
2. J.G.F. Cleland, A. Cohen-Solal, J.C. Aguilar, R. Dietz, J. Eastaugh, F. Follath IMPROVEMENT of Heart Failure Programme Committees and Investigators Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey Lancet 360 2002 1631 1639
3. S.S. Gottlieb, M.L. Fischer, J. Kjekshus, P. Deedwania, L. Gullestad, J. Vitovec MERIT-HF Investigators Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Circulation 105 2002 1182 1188
4. 1- adrenergic receptor J Biol Chem 274 1999 12670 12674
5. 1-adrenoceptors in isolated human atrial myocardium Br J Pharmacol 138 2003 386 392
6. 1-adrenergic receptor polymorphisms in human right atrium in vitro J Am Coll Cardiol 40 2002 1275 1282
7. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo Pharmacogenetics 11 2001 191 197
8. 1-adrenoceptor polymorphism in humans Pharmacogenetics 11 2001 199 205
9. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol Clin Pharmacol Ther 74 2003 44 52
10. 1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade Clin Pharmacol Ther 73 2003 366 371
11. 1-adrenergic receptor is associated with the cardiovascular response to metoprolol Clin Pharmacol Ther 74 2003 372 379
12. J. Mialet Perez, D.A. Rathz, N.N. Petrashevskaya, H.S. Hahn, L.E. Wagoner, A. Schwartz Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure Nat Med 9 2003 1300 1305
13. D.A. Rathz, K.M. Brown, L.A. Kramer, S.B. Liggett Amino acid polymorphism of the human beta 1-adrenergic receptor affect agonist-promoted trafficking J Cardiovasc Pharmacol 39 2002 155 160
14. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J Biol Chem 277 2002 30429 30435
15. M. Borjesson, Y. Magnusson, Y. Hjalmarson, B. Andersson A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure Eur Heart J 21 2000 1853 1858
16. V. Dishy, G.G. Sofowora, H.G. Xie, R.B. Kim, D.W. Byrne, C.M. Stein The effect of common polymorphisms of the beta-2-adrenergic receptor on agonist-mediated vascular desensitization N Engl J Med 345 2001 1030 1035
17. H. Jia, A.D. Hingorani, P. Sharma, R. Hopper, C. Dickerson, D. Trutwein Association of the G(s) alpha gene with essential hypertension and response to beta-blockade Hypertension 34 1999 8 14
18. D.M. Kaye, B. Smirk, C. Williams, G. Jennings, M. Esler, D. Holst Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure Pharmacogenetics 13 2003 379 382
19. G.H. Guyatt, M.J. Sullivan, P.J. Thompson, E.L. Fallen, S.O. Pugsley, D.W. Taylor The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure Can Med Assoc J 132 1985 919 923
20. T.S. Rector, J.N. Cohn Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan Pimobendan Multicenter Research Group Am Heart J 124 1992 1017 1025
21. J.A. Johnson, B.S. Burlew Metoprolol metabolism via cytochrome P4502D6 in ethnic populations Drug Metab Dispos 24 1996 350 355
22. S.G. Terra, S.P. McGorray, M.R. Wallace, L. Picoult-Newberg, C.J. Pepine, J.A. Johnson Linkage disequilibrium of common beta-1 adrenergic receptor polymorphisms [abstract] Clin Pharmacol Ther 71 2002 P70
23. Bell PA, Chaturvedi S, Gelfand CA, Huang CY, Kochersperger M, Kopla R, et al. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques 2002;Suppl:70-2, 74, 76-7.
24. S. Kimura, M. Umeno, R.C. Skoda, U.A. Meyer, F.J. Gonzalez The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene Am J Hum Genet 45 1989 889 904
25. A. Gaedigk, R.R. Gotschall, N.S. Forbes, S.D. Simon, J.S. Leeder Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data Pharmacogenetics 9 1999 669 682
26. E.U. Griese, U.M. Zanger, U. Brudermanns, A. Gaedigk, G. Mikus, K. Morike Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population Pharmacogenetics 8 1998 15 26
27. K.A. Marcucci, R.E. Pearce, C. Crespi, J.S. Leeder, A. Gaedigk Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2 and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine Drug Metab Dispos 30 2002 1 7
28. S. Raimundo, J. Fischer, M. Eichelbaum, E.U. Griese, M. Schwab, U.M. Zanger Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6 Pharmacogenetics 10 2000 577 581
29. M. Oscarson, M. Hidestrand, I. Johansson, M. Ingelman-Sundberg A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function Mol Pharmacol 52 1997 1034 1040
30. C. Sachse, J. Brockmoller, S. Bauer, I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 265 271
31. R.L. Anthonio, D.J. van Veldhuisen, A. Breekland, H.J.G.M. Crijns, W.H. van Gilst Beta-blocker titration failure is independent of severity of heart failure Am J Cardiol 85 2000 509 512
32. D.M. Mancini, H. Eisen, W. Kussmaul, R. Mull, L.H. Edmunds Jr, J.R. Wilson Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure Circ Res 83 1991 778 786
33. 1-adrenergic receptor predict exercise capacity in heart failure Am Heart J 144 2002 840 846
34. 1- adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy J Mol Cell Cardiol 31 1999 1025 1032
35. C.G. Regardh, G. Johnsson Clinical pharmacokinetics of metoprolol Clin Pharmacokinet 5 1980 557 569
36. A.M. Meadowcroft, K.M. Williamson, J.H. Patterson, J.A. Pieper Pharmacogenetics and heart failure: a convergence with carvedilol Pharmacotherapy 17 1997 637 639
37. A.L. Beitelshees, I. Zineh, A. Gaedigk, J.S. Leeder, J.R. Walker, K. Eberst Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects [abstract] Clin Pharmacol Ther 75 2004 P94
38. K.M. Sowinski, B.S. Burlew, J.A. Johnson Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy males Clin Pharmacol Ther 57 1995 678 683
39. 2-adrenergic receptor determine exercise capacity in patients with heart failure Circ Res 86 2000 834 840
40. H. Krum, E.B. Roecker, P. Mohacsi, J.L. Rouleau, M. Tendera, A.J. Coats Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 2003 712 718
41. K.A. Schleman, J.A. Lindenfeld, B.D. Lowes, M.R. Bristow, D. Ferguson, E.E. Wolfel Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis J Card Fail 7 2001 4 12